ARTICLE | Company News
3SBio gets Chinese rights to Byetta, Bydureon
October 11, 2016 7:00 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) granted 3SBio Inc. (HKSE:1530) an exclusive license to commercialize diabetes drugs Byetta exenatide and its once-weekly form Bydureon in China. 3SBio is paying AstraZeneca $50 million up front and up to $50 million in milestones.
According to 3SBio, AstraZeneca recorded $14.6 million in 2015 revenues in China for the products. ...